ReviewAIMS microbiology2026
Molecular biophysics of viral proteins: From mechanistic insights to microbiological and clinical applications.
Review in AIMS microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral proteins are dynamic molecular machines that couple molecular-scale events to microbiological phenotypes, including host-cell tropism, entry efficiency, environmental persistence, strain-specific immune escape, and antiviral resistance. In this review, we critically evaluated how experimental, computational, and biochemical approaches define these links and support clinical translation. We organized the evidence around four key observables: Structure, dynamics, mechanics, and thermodynamics. We then assessed which conclusions remained robust across methods and viral families. Nuclear magnetic resonance spectroscopy, cryogenic electron microscopy, atomic force microscopy, calorimetry, all-atom molecular dynamics (MD), coarse-grained MD, structural bioinformatics, artificial intelligence, and biochemical reconstitution were compared in terms of resolution, sampling, assumptions, and validation requirements. Human immunodeficiency virus type 1 and severe acute respiratory syndrome coronavirus 2 were used as data-rich exemplars, but the resulting conclusions were tested against influenza virus, hepatitis B virus (HBV), human papillomavirus (HPV), Ebola virus, adenovirus, bacteriophages, and other systems. Particular attention was given to force-field selection, enhanced sampling, free-energy calculations, convergence, experimentally restrained modeling, and the multiscale relationship between all-atom and coarse-grained simulations. We also examined integrative workflows, the licensed HBV and HPV virus-like particle (VLP) vaccines, emerging dengue and coronavirus VLP platforms, and clinically validated structure-guided antivirals and prefusion-stabilized antigens. The analysis identified where evidence converges, where method-specific biases or limited taxonomic sampling constrain generalization, and which measurements are required to connect a molecular mechanism to infection, transmission-relevant traits, surveillance, or therapeutic performance. This critical, experimentally anchored framework defines the distinctive contribution of the review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.